136
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Leptin, Galectin-3 and Angiotensin II Type 1 Receptor Polymorphism in Overweight and Obese Patients with Heart Failure – Role and Functional Interplay

ORCID Icon, ORCID Icon, , ORCID Icon, , , , , , & ORCID Icon show all
Pages 1727-1737 | Published online: 06 May 2021

References

  • Barbosa-Ferreira JM, Fernandes F, Dabarian A, Mady C. Leptin in heart failure. Expert Opin Med Diagn. 2013;7(1):113–117. doi:10.1517/17530059.2013.735229
  • Dădârlat-Pop A, Sitar-Tăut A, Zdrenghea D, et al. Profile of obesity and comorbidities in elderly patients with heart failure. Clin Interv Aging. 2020;15:547–556. doi:10.2147/CIA.S248158
  • Iwai M, Horiuchi M. Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res. 2009;32(6):425–427. doi:10.1038/hr.2009.55
  • Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and Cardiac Remodeling in Adults: mechanisms and Clinical Implications. Prog Cardiovasc Dis. 2018;61(2):114–123. doi:10.1016/j.pcad.2018.07.012
  • Szabó T, Scherbakov N, Sandek A, et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis. 2014;24(1):50–56. doi:10.1016/j.numecd.2013.04.015
  • Packer M. Leptin-Aldosterone-Neprilysin Axis: identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. Circulation. 2018;137(15):1614–1631. doi:10.1161/CIRCULATIONAHA.117.032474
  • Chow SL, Maisel AS, Anand I, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: a Scientific Statement From the American Heart Association. Circulation. 2017;135(22):e1054–e1091. doi:10.1161/CIR.0000000000000490
  • Piek A, Du W, de Boer RA, Sillje HHW. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci. 2018;55(4):246–263. doi:10.1080/10408363.2018.1460576
  • Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in Heart Failure: an Update of the Last 3 Years. Heart Fail Clin. 2018;14(1):75–92. doi:10.1016/j.hfc.2017.08.009
  • Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33(17):2197–2205. doi:10.1093/eurheartj/ehs136
  • Farooqi IS, O’Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014;223(1):T63–70. doi:10.1530/JOE-14-0480
  • Menini S, Iacobini C, Blasetti Fantauzzi C, Pesce CM, Pugliese G. Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis. Oxid Med Cell Longev. 2016;2016:9618092. doi:10.1155/2016/9618092
  • Mishra A, Srivastava A, Kumar S, et al. Role of angiotensin II type I (AT1 A1166C) receptor polymorphism in susceptibility of left ventricular dysfunction. Indian Heart J. 2015;67(3):214–221. doi:10.1016/j.ihj.2015.04.013
  • Dadarlat A, Pop D, Procopciuc L, Buzoianu A. Links between renin-angiotensin system genetic polymorphisms and leptin secretion in obese heart failure patients. Acta Endo. 2018;14(2):274–279. doi:10.4183/aeb.2018.274
  • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw128
  • Dadarlat A, Pop D, Farcas AD, et al. Can the presence of atrial fibrillation influence the levels of heart failure - specific biomarkers in overweight and obese patients with heart failure?, Rev. Chim. 2019;70(6):2294–2300.
  • Takemoto Y, Sakatani M, Takami S, et al. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax. 1998;53(6):459–462. doi:10.1136/thx.53.6.459
  • Wolk R, Somers VK. Leptin and vascular function: friend or foe? Eur Heart J. 2006;27(19):2263–2265. doi:10.1093/eurheartj/ehl246
  • Berzabá-Evoli E, Zazueta C, Cruz Hernández JH, et al. Leptin modifies the rat heart performance associated with mitochondrial dysfunction independently of its prohypertrophic Effects. Int J Endocrinol. 2018;2018:6081415. doi:10.1155/2018/6081415
  • Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O, Sattar N. The obesity paradox in men with coronary heart disease and heart failure: the role of muscle mass and leptin. Int J Cardiol. 2014;171(1):49–55. doi:10.1016/j.ijcard.2013.11.043
  • Nasri H. Serum leptin concentration and left ventricular hypertrophy and function in maintenance hemodialysis patients. Minerva Urol Nefrol. 2006;58(2):189–193.
  • Khafaji HA, Bener AB, Rizk NM, Al Suwaidi J. Elevated serum leptin levels in patients with acute myocardial infarction; correlation with coronary angiographic and echocardiographic findings. BMC Res Notes. 2012;5(1):262. doi:10.1186/1756-0500-5-262
  • Van Berendoncks AM, Garnier A, Ventura-Clapier R, Conraads VM. Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure. Heart Fail Rev. 2013;18(5):557–566. doi:10.1007/s10741-012-9349-4
  • Deswal A. Obesity, leptin, and incident heart failure. J Am Coll Cardiol. 2011;58(18):1878–1880. doi:10.1016/j.jacc.2011.07.030
  • Lieb W, Sullivan LM, Harris TB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individual. Diabetes Care. 2009;32(4):612–616. doi:10.2337/dc08-1596
  • Castellano M, Glorioso N, Cusi D, et al. Genetic polymorphism of the renin-angiotensin- aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J Hypertens. 2003;21(10):1853–1860. doi:10.1097/00004872-200310000-00012
  • Baudin B. Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol. 2005;90(3):277–282. doi:10.1113/expphysiol.2004.028456
  • Głuszek J, Jankowska K. Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy? Pol Arch Med Wewn. 2008;118(4):194–200.
  • Pop D, Zdrenghea D, Procociuc LM, Popa A. Gene polymorphism of angiotensin- converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure. Rom J Intern Med. 2007;45(4):349–354.
  • Pop D. Sistemul Renină-Angiotensină-Aldosteron În Patogeneza Bolilor Cardiovasculare. Ed. Clusium. Cluj-Napoca; 2007.
  • Mishra A, Srivastava A, Mittal T, Garg N, Mittal B. Genetic predisposition to left ventricular dysfunction: a multigenic and multi-analytical approach. Gene. 2014;546(2):309–317. doi:10.1016/j.gene.2014.05.060
  • Pintérová L, Zelezná B, Ficková M, et al. Elevated AT1 receptor protein but lower angiotensin II-binding in adipose tissue of rats with monosodium glutamate-induced obesity. Horm Metab Res. 2001;33(12):708–712. doi:10.1055/s-2001-19132
  • French B, Wang L, Ky B, et al. Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail. 2016;22(4):256–262. doi:10.1016/j.cardfail.2015.10.022